Contents

FOREWORD

WHAT TECHNOLOGY DO WE HAVE AND HOW IS IT DOING?

Measurement of Pore Size and Porosity of Tissue Scaffolds—P. TOMLINS, P. GRANT, S. MIKHALOVSKY, S. JAMES, AND L. MIKHALOVSKA 3

Development and Validation of a Detection Method for a Broad Range of Human Papillomavirus Types—D. N. GALBRAITH, T. COLLINS, J. BLACK, B. MC MANUS, D. MC MUTRIE, AND A. LOVATT 12


NIST and Standards for Tissue Engineered Medical Products—J. A. TESK AND L. R. KARAM 40


Method to Determine Germicidal Inactivation in Allograft Processing—C. R. MILLS, M. R. ROBERTS, J. Y. CHANG, J. R. BIANCHI, AND M. C. SUMMITT 54


Age Related Differences in Chondrocyte Viability and Biosynthetic Response To Mechanical Injury—D. D’LIMA, A. BERGULA, P. C. CHEN, C. W. COLWELL, AND M. LOTZ 77
A Comparative Study of Biomarkers of Oxidative DNA Damage Used to Detect Free Radical Damage in Tissue-Engineered Skin—H. RODRIGUEZ, P. JARUGA, M. BIRINCIOGLU, P. E. BARKER, C. O’CONNOR, AND M. DIZDAROGLU 84

Endpoint Verification of Bone Demineralization for Tissue Engineering Applications—C. B. THOMAS, L. JENKINS, J. F. KELLAM, AND K. J. L. BURG 90

Comparative Study of Bone Cell Culture Methods for Tissue Engineering Applications—C. B. THOMAS, J. F. KELLAM, AND K. J. L. BURG 100

A New Method for Real-Time and In-Situ Characterization of the Mechanical and Material Properties of Biological Tissue Constructs—G. ZHANG AND J. L. GILBERT 120

WHAT STANDARDS EXIST AND WHAT STANDARDS ARE NEEDED?

Alginate and Chitosan Standards for Tissue Engineered Medical Products—M. DORNISH AND A. Dessen 137


Development of Standards for the Characterization of Natural Materials Used in Tissue Engineered Medical Products (TEMPs)—D. KAPLAN 172

Microbiological Safety and Adventitious Agents Standards for TEMPS—G. SOFER 176

Standards Used in Meeting Requirements for a Model Pre-Market Approval (PMA) of a Neural Guidance Conduit—L. STOVER AND L. HUBEL 182


WHAT STANDARDS ARE USED GLOBALLY AND HOW BY THE REGULATORY BODIES FOR APPROVALS?

The European Situation on Standards for Tissue Engineering Products—E. SCHUTTE 213

A European View on Risk Management Strategies for Tissue Engineered Medical Products (TEMPs)—R. E. GEERTSMA, M. KALLEWAARD, AND C. WASSENAAAR 226


A Useful Marker for Evaluating the Safety and Efficacy of Tissue Engineered Products—T. TSUCHIYA 254

AUTHOR INDEX 263

SUBJECT INDEX 265